Search Results

You are looking at 1 - 10 of 318 items for :

  • "fluorouracil" x
  • All content x
Clear All
Full access

Yixing Jiang, Heath Mackley, Hua Cheng, and Jaffer A. Ajani

. The Evolving Role of Chemoradiation in Locoregionally Confined Disease Role of 5-Fluorouracil and Mitomycin C in Chemoradiation Abdominoperineal resection was the foundation in the management of locoregionally confined squamous cell carcinoma of

Full access

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Anne Covey, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, Krystyna Kiel, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Sujata Rao, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett

advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group [abstract] . J Clin Oncol 2008 ; 26 ( Suppl 1 ): Abstract LBA 4011 . 35 Bokemeyer C Bondarenko I Makhson A . Fluorouracil, leucovorin, and oxaliplatin with and

Full access

Zachary Veitch, Omar F. Khan, Derek Tilley, Patricia A. Tang, Domen Ribnikar, Douglas A. Stewart, Xanthoula Kostaras, Karen King, and Sasha Lupichuk

breast cancer mortality for first-generation regimens (ie, cyclophosphamide/methotrexate/fluorouracil [CMF]) and increased benefit with the addition of anthracyclines and taxanes. 1 Although some meta-analyses have shown the benefits of dose

Full access

Zachary Veitch, Omar F. Khan, Derek Tilley, Domen Ribnikar, Xanthoula Kostaras, Karen King, Patricia Tang, and Sasha Lupichuk

exists comparing FEC-DH (fluorouracil/epirubicin/cyclophosphamide followed by docetaxel/trastuzumab) versus either TCH or AC followed by taxane/trastuzumab in the adjuvant setting despite inclusion in ASCO guidelines. 16 We retrospectively evaluated

Full access

Zhi Ven Fong and Cristina R. Ferrone

horizon for patients with metastatic PDAC significantly changed with the multiagent chemotherapy regimens fluorouracil/folinic acid/irinotecan/oxaliplatin (FOLFIRINOX) 4 and gemcitabine/nab-paclitaxel, 5 respectively. Median survival for patients with

Full access

Robin K. Kelley, Stephanie L. Van Bebber, Kathryn A. Phillips, and Alan P. Venook

case study focuses on the possible role of MMR deficiency as a predictive factor for lack of benefit from 5-fluorouracil chemotherapy in patients with stage II colon cancer. Among the 16 nonrandomized studies identified by this search, several suggest

Full access

Paul F. Engstrom

2002, the NCCN panel advocated 5-fluorouracil (5-FU)/leucovorin adjuvant therapy for stage III or node-positive disease and 5-FU leucovorin with or without irinotecan (IFL) as first-line therapy for metastatic disease. Second-line therapies for

Full access

Neelima Denduluri, Debra A. Patt, Yunfei Wang, Menaka Bhor, Xiaoyan Li, Anne M. Favret, Phuong Khanh Morrow, Richard L. Barron, Lina Asmar, Shanmugapriya Saravanan, Yanli Li, Jacob Garcia, and Gary H. Lyman

myelosuppressive agent. Error bars indicate 95% CI. Abbreviations: 5-FU, 5-fluorouracil; ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; AC, doxorubicin, cyclophosphamide; CRC, colorectal cancer; FOLFOX4/mFOLFOX6, folinic acid, 5-fluorouracil, oxaliplatin

Full access

Lee S. Schwartzberg and Sarah L. Blair

: AC, anthracycline/cyclophosphamide; CMF, cyclophosphamide/methotrexate/fluorouracil; doc, docetaxel; G-CSF, granulocyte colony-stimulating factor; pts, patients; T, paclitaxel; TC, docetaxel/cyclophosphamide; TCH, docetaxel

Full access

Joseph Rosales and Lucille A. Leong

discussed in the article or their competitors. References 1 Poon MA O'Connell MJ Wieand HS . Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer . J Clin